HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Fundamental Analysis
Europe - EBR:HYL - BE0974363955 - Common Stock
5.98 EUR
+0.3 (+5.28%)
Overall HYL gets a fundamental rating of 4 out of 10. We evaluated HYL against 54 industry peers in the Pharmaceuticals industry. HYL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HYL shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
HYL had negative earnings in the past year.
HYL had a negative operating cash flow in the past year.
HYL had negative earnings in each of the past 5 years.
In the past 5 years HYL always reported negative operating cash flow.
1.2 Ratios
HYL has a Return On Assets of -17.31%. This is in the lower half of the industry: HYL underperforms 75.93% of its industry peers.
HYL's Return On Equity of -22.20% is on the low side compared to the rest of the industry. HYL is outperformed by 74.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.31% | ||
| ROE | -22.2% | ||
| ROIC | N/A |
ROA(3y)-22.4%
ROA(5y)-19.16%
ROE(3y)-27.06%
ROE(5y)-23.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 96.63%, HYL belongs to the top of the industry, outperforming 98.15% of the companies in the same industry.
In the last couple of years the Gross Margin of HYL has grown nicely.
The Profit Margin and Operating Margin are not available for HYL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.27%
GM growth 5Y28.78%
2. Health
2.1 Basic Checks
HYL does not have a ROIC to compare to the WACC, probably because it is not profitable.
HYL has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, HYL has more shares outstanding
The debt/assets ratio for HYL is higher compared to a year ago.
2.2 Solvency
HYL has an Altman-Z score of 8.62. This indicates that HYL is financially healthy and has little risk of bankruptcy at the moment.
HYL has a Altman-Z score of 8.62. This is amongst the best in the industry. HYL outperforms 98.15% of its industry peers.
HYL has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
HYL has a better Debt to Equity ratio (0.06) than 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.62 |
ROIC/WACCN/A
WACC7.84%
2.3 Liquidity
A Current Ratio of 3.82 indicates that HYL has no problem at all paying its short term obligations.
The Current ratio of HYL (3.82) is better than 90.74% of its industry peers.
A Quick Ratio of 3.80 indicates that HYL has no problem at all paying its short term obligations.
HYL has a better Quick ratio (3.80) than 90.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.82 | ||
| Quick Ratio | 3.8 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 46.52% over the past year.
Looking at the last year, HYL shows a very strong growth in Revenue. The Revenue has grown by 44.15%.
Measured over the past years, HYL shows a very strong growth in Revenue. The Revenue has been growing by 147.54% on average per year.
EPS 1Y (TTM)46.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.01%
Revenue 1Y (TTM)44.15%
Revenue growth 3Y39.79%
Revenue growth 5Y147.54%
Sales Q2Q%-27.33%
3.2 Future
Based on estimates for the next years, HYL will show a very strong growth in Earnings Per Share. The EPS will grow by 44.80% on average per year.
HYL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 94.06% yearly.
EPS Next Y38.32%
EPS Next 2Y31.09%
EPS Next 3Y44.8%
EPS Next 5YN/A
Revenue Next Year11.58%
Revenue Next 2Y67.28%
Revenue Next 3Y94.06%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
HYL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HYL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as HYL's earnings are expected to grow with 44.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.09%
EPS Next 3Y44.8%
5. Dividend
5.1 Amount
HYL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EBR:HYL (11/17/2025, 10:38:41 AM)
5.98
+0.3 (+5.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners56.74%
Ins Owner ChangeN/A
Market Cap167.44M
Revenue(TTM)7.32M
Net Income(TTM)-6.41M
Analysts80
Price Target13.7 (129.1%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.05%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.98%
EPS NY rev (3m)16.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)10.6%
Revenue NY rev (3m)-20.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 22.86 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.8 | ||
| P/tB | 6.72 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.26
BVpS1.03
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.31% | ||
| ROE | -22.2% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.63% | ||
| FCFM | N/A |
ROA(3y)-22.4%
ROA(5y)-19.16%
ROE(3y)-27.06%
ROE(5y)-23.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.27%
GM growth 5Y28.78%
F-Score3
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 69.05% | ||
| Cap/Sales | 6.46% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.82 | ||
| Quick Ratio | 3.8 | ||
| Altman-Z | 8.62 |
F-Score3
WACC7.84%
ROIC/WACCN/A
Cap/Depr(3y)212.59%
Cap/Depr(5y)303.89%
Cap/Sales(3y)40.52%
Cap/Sales(5y)102.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.01%
EPS Next Y38.32%
EPS Next 2Y31.09%
EPS Next 3Y44.8%
EPS Next 5YN/A
Revenue 1Y (TTM)44.15%
Revenue growth 3Y39.79%
Revenue growth 5Y147.54%
Sales Q2Q%-27.33%
Revenue Next Year11.58%
Revenue Next 2Y67.28%
Revenue Next 3Y94.06%
Revenue Next 5YN/A
EBIT growth 1Y55.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.21%
EBIT Next 3Y108.64%
EBIT Next 5YN/A
FCF growth 1Y36.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.99%
OCF growth 3YN/A
OCF growth 5YN/A
HYLORIS PHARMACEUTICALS SA / HYL.BR FAQ
What is the fundamental rating for HYL stock?
ChartMill assigns a fundamental rating of 4 / 10 to HYL.BR.
What is the valuation status for HYL stock?
ChartMill assigns a valuation rating of 1 / 10 to HYLORIS PHARMACEUTICALS SA (HYL.BR). This can be considered as Overvalued.
Can you provide the profitability details for HYLORIS PHARMACEUTICALS SA?
HYLORIS PHARMACEUTICALS SA (HYL.BR) has a profitability rating of 1 / 10.
What is the earnings growth outlook for HYLORIS PHARMACEUTICALS SA?
The Earnings per Share (EPS) of HYLORIS PHARMACEUTICALS SA (HYL.BR) is expected to grow by 38.32% in the next year.